RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:528647

Hereditary angioedema with normal C1Inh

high confidenceDisorder

Also known as: HAE with normal C1 inhibitor · HAE with normal C1Inh · Hereditary angioedema with normal C1 inhibitor · Hereditary angioneurotic edema with normal C1 inhibitor · Hereditary angioneurotic edema with normal C1Inh

Publications

310

81.4th percentile

Trials

0

Interventional, condition-specific

Researchers

1,107

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare angioedema characterized by potentially life-threatening episodes of subcutaneous and/or submucosal edema without urticaria and with normal levels and function of C1 esterase inhibitor. Patients present with prolonged attacks which last for approximately two to five days and may include nonpitting edema of the skin, severe abdominal symptoms such as pain and swelling, and/or respiratory distress due to upper respiratory airways involvement. Affected locations and frequency of attacks differ slightly between subtypes. Estrogen-containing oral contraceptives and pregnancy are precipitating factors, especially in patients with a factor XII mutation.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

hereditary angioedema with normal C1 inhibitor · hereditary angioneurotic edema with normal C1 inhibitor · hereditary angioneurotic edema with normal C1Inh

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    310 matched papers (240 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 118 for broader category hereditary angioedema

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

310

310 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

310 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

240 in the last 10 years · high confidence · 81.4th percentile (publications denominator)

Phrase hits: 310 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,107

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Bork K21 papers · 2025

    11Department of Dermatology, University Hospital of the Johannes Gutenberg-University of Mainz, Mainz, Germany.

    Papers in Europe PMC
  2. 02
    Grumach AS21 papers · 2026

    Clinical Immunology, Faculdade de Medicina, Centro Universitario Faculdade de Medicina ABC (CEUFMABC), Santo Andre, Brazil.

    Papers in Europe PMC
  3. 03
    Bouillet L14 papers · 2026

    National Reference Center for Angioedema (CREAK), Department of Internal Medicine/Clinical Immunology, Grenoble Alpes University Hospital, Grenoble, France.

    Papers in Europe PMC
  4. 04
    Bernstein JA13 papers · 2026

    Division of Immunology, Rheumatology, and Allergy, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.

    Papers in Europe PMC
  5. 05
    Magerl M13 papers · 2026

    Institute of Allergology, Charité - Universitätsmedizin [Charité University Medical Department] Berlin and Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP [Fraunhofer Institute for Translational Medicine and Pharmacology], Standort Allergologie und Immunologie [Allergology and Immunology], Berlin, Germany.

    Papers in Europe PMC
  6. 06
    Riedl MA12 papers · 2026

    Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, Calif.

    Papers in Europe PMC
  7. 07
    Arruda LK10 papers · 2026

    Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Center for Genomic Medicine, Clinical Hospital of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: karla@fmrp.usp.br.

    Papers in Europe PMC
  8. 08
    Banerji A10 papers · 2026

    Division of Rheumatology, Allergy and Immunology, Department of Medicine, Harvard Medical School, Boston, Mass.

    Papers in Europe PMC
  9. 09
    Boccon-Gibod I10 papers · 2026

    Department of Internal Medicine National Reference Centre for Angioedema (CREAK) Université Grenoble Alpes, Joint Unit 1036 INSERM-CNRS-CEA CHU Grenoble France.

    Papers in Europe PMC
  10. 10
    Farkas H10 papers · 2026

    Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary. farkas.henriette@med.semmelweis-univ.hu.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 118 trials are registered for hereditary angioedema, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

118 interventional trials matched hereditary angioedema, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: hereditary angioedema

118

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

Likely covered — the policy lists Hereditary angioedema as a category (Group 3), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.

Group 3 — high-cost / lifelong therapy with careful selection

Up to ₹50 lakh per patient

Financial support at notified Centres of Excellence is the figure commonly cited in recent MoHFW/PIB statements. Many Group 3 patients also use the MoHFW voluntary-contribution / crowdfunding portal.

Eligibility and patient selection rules change. Verify with a CoE; the crowdfunding portal is a separate mechanism from CoE funding. Verify

Centres of Excellence (15)
  • All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
  • Maulana Azad Medical College — New Delhi, Delhi
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
  • Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
  • Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
  • King Edward Memorial Hospital — Mumbai, Maharashtra
  • Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
  • Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
  • Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
  • All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
  • Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
  • All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
  • Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
  • All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
  • Assam Medical College & Hospital — Dibrugarh, Assam

Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Hereditary angioedema with normal C1Inh" OR "HAE with normal C1 inhibitor" OR "HAE with normal C1Inh" OR "Hereditary angioedema with normal C1 inhibitor" OR "Hereditary angioneurotic edema with normal C1 inhibitor" OR "Hereditary angioneurotic edema with normal C1Inh"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Hereditary angioedema with normal C1Inh" OR "HAE with normal C1 inhibitor" OR "HAE with normal C1Inh" OR "Hereditary angioedema with normal C1 inhibitor" OR "Hereditary angioneurotic edema with normal C1 inhibitor" OR "Hereditary angioneurotic edema with normal C1Inh"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"hereditary angioedema"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T18:05:49.176Z